SRZN
Surrozen, Inc.
Price as of Jul 20, 2026
SRZN earnings
Surrozen, Inc. earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-1.39 | $-4.63 | -233.1% | $5M | +25.0% |
| Mar 23, 2026 | $-1.41 | $-7.59 | -438.3% | $528000 | -20.1% |
| Nov 7, 2025 | $-1.17 | $-3.61 | -208.5% | $983000 | — |
| Aug 8, 2025 | $-1.23 | $-1.14 | +7.3% | $983000 | — |
| May 9, 2025 | $-1.09 | $-3.13 | -187.2% | $983000 | — |
| Mar 31, 2025 | $-2.54 | $-9.10 | -258.3% | $655000 | — |
| May 8, 2024 | $-4.25 | $-4.24 | +0.2% | — | — |
| May 10, 2023 | $-5.10 | $-7.20 | -41.2% | — | — |
| Mar 22, 2023 | $-6.75 | $-0.45 | +93.3% | $13M | — |
| Nov 14, 2022 | $-6.45 | $-5.70 | +11.6% | — | — |
| Aug 11, 2022 | $-6.90 | $-6.00 | +13.0% | — | — |
| Mar 24, 2022 | $-7.80 | $-5.25 | +32.7% | — | — |
Earnings call summary
Q4 FY2022 · March 25, 2023
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Surrozen is an innovator in using the Wnt pathway for tissue regeneration with proprietary technologies. - Focused on 2 key clinical areas: SZN-043 for severe alcoholic hepatitis and SZN-1326 for inflammatory bowel disease. - Updates on clinical trials: SZN-043 has enrolled first patient in chronic liver disease study, SZN-1326 to progress with modified dosing strategy. - Partnership with Boehringer Ingelheim, with potential milestone by year-end 2023. - Research programs for cornea, lacrimal gland, and ophthalmologic indications like dry eye.
Guidance
- Cash runway into second half of 2024. - SZN-043 expected to have data from Phase I single ascending dose in chronic liver disease patients by year-end 2023, Phase Ib in 2024. - SZN-1326 expected to have data by year-end 2023, Phase Ib in 2024. - Boehringer Ingelheim partnership to nominate candidate by year-end 2023, triggering $10M milestone.
Segment performance
No specific product segment financial performance with revenue contribution % discussed in detail
Risks & headwinds
- Transaminase elevations observed in clinical trials, not fully understood mechanistically. - Uncertainties in translating preclinical data to human responses, especially in hepatically-impaired patients. - Potential challenges in mitigating liver-related adverse events in more hepatically-impaired patients.
Analyst Q&A
Q: Clarification on SZN-043 study plans, change in target population from early cirrhotic to chronic liver disease, and strategy to mitigate transaminase observations in hepatically-impaired patients.
A: SZN-043 target population includes chronic liver disease patients with fibrosis, not necessarily frank cirrhosis. No specific mechanistic strategy to mitigate yet, but damaged tissue may be more sensitive.
Q: Half-life of SZN-1326 and expected dosing regimens for multiple ascending dose study.
A: Half-life of SZN-1326 is about 5 days. Dosing regimen not finalized, but could be every other week or less.
Q: Target engagement for SZN-043 and SZN-1326, dose response, and confidence in 0.5 dose for biological activity.
A: For SZN-043, target engagement confirmed via ALP elevation, 0.5 dose in range for potential therapeutic activity. For SZN-1326, target engagement to be confirmed by Axin2 assay in UC patient biopsies.
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-08-14.